Clonal Hematopoiesis of Indeterminate Potential in Venous Thromboembolism

Venous Thromboembolism Clinical Trial

— CHIPS  

Official title:

Screening of Clonal Hematopoiesis of Indeterminate Potential in Venous Thromboembolism

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04477564
• Other study ID #: NIMAO/2020-01/SB-01
• Status: Completed
• Start date: July 3, 2020
• Est. completion date: December 30, 2022

Study information

• Verified date: June 2023
• Source: Centre Hospitalier Universitaire de Nimes
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The aim of the study is to investigate the existence of clonal hematopoiesis of indeterminate potential (CHIP) in patients with a history of venous thromboembolism.

The study investigators make the assumption that these patients present mutations involved in CHIP occurrence.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 150
• Est. completion date: December 30, 2022
• Est. primary completion date: December 30, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 50 Years and older

Eligibility

Inclusion Criteria:

• Men and women over 50 years old who have consulted at the Hematology laboratory of the Nîmes University Hospital for the occurrence or history of venous thromboembolism

• Patient who has accepted that their DNA was kept and used in the context of research on venous thromboembolism (biobank (registration number DC-2008-290 and authorization number AC-2008-107))

Exclusion Criteria:

• Patients less than 50 years old

• Patient who has refused that their DNA was kept and used in the context of research on venous thromboembolism

Related Conditions & MeSH terms

• Thromboembolism
• Venous Thromboembolism

Locations

Country	Name	City	State
France	CHU de Nimes	Nîmes

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	DNMT3A mutations screening	Next generation sequencing	For sequencing analysis: 2 months
Secondary	TET2, ASXL1, TP53, JAK2, SF3B1, SRSF2, GNB1, CBL, BCOR, SH2B3, PPM1D mutations screening	Next generation sequencing	For sequencing analysis: 2 months